Radiofrequency Ablation for Hepatocellular Carcinoma: Assistant Techniques for Difficult Cases
Tatsuo Inoue, Masatoshi Kudo(Kindai University), Satoru Hagiwara(Kindai University Hospital), Hobyung Chung(Kindai University), Masahiro Takita(Kindai University), Satoshi Kitai(Kindai University), Yasunori Minami, Kazuomi Ueshima(Kindai University), Kinuyo Hatanaka(Union Hospital), Emi Ishikawa(Kyowa Chemical Industry (Japan)), Norihisa Yada(Kindai University), Sousuke Hayaishi(Kindai University), Taisuke Ueda(Kindai University), Chie Tatsumi(Kindai University)
Cited by 33
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k